Insulin - Adverse effects
Research News and Information

Saturday, November 21, 2009

Three-year efficacy of complex insulin regimens in type 2 diabetes.

20 Oct 2009 BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal ... Read more...

Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.

29 Sep 2009 OBJECTIVE: To report a case of leukocytoclastic vasculitis associated with insulin aspart therapy. CASE SUMMARY: A 56-year-old man was admitted to the Department of Endocrinology because of a poorly controlled Type 2 diabetes. In an attempt to reach ... Read more...

Intensive insulin therapy confers a similar survival benefit in the burn intensive care unit to the surgical intensive care unit.

3 Sep 2009 BACKGROUND: In contrast to the benefits of intensive insulin therapy (IIT) in the surgical intensive care unit (SICU), its benefits in the burn ICU (BICU) remain unclear. Furthermore, IIT and tight glycemic control has received little attention in ... Read more...

Latest indexed articles for 'Insulin - Adverse effects'

These are the very latest articles for this heading:

• Images in clinical medicine. Injection-site lipoatrophy. 3 Nov 2009
• Three-year efficacy of complex insulin regimens in type 2 diabetes. 20 Oct 2009
• Could insulin sensitization be used as an alternative to intensive insulin therapy to improve the survival of intensive care unit patients with stress-induced hyperglycemia? 29 Sep 2009
• Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes. 29 Sep 2009
• Intensive insulin therapy confers a similar survival benefit in the burn intensive care unit to the surgical intensive care unit. 3 Sep 2009
• Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. 30 Aug 2009
• Hypoglycemia and intensive insulin therapy: strict vigilance and prompt correction. 30 Aug 2009
• [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart] 28 Aug 2009
• Insulin glargine (Lantus) and cancer risk. 22 Aug 2009
• Insulin glargine and cancer: another side to the story? 13 Aug 2009
• Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. 12 Aug 2009
• Hypoglycemia: from the laboratory to the clinic. 30 Jul 2009
• Glucose sensing during hypoglycemia: lessons from the lab. 30 Jul 2009
• Rapid desensitization for hypersensitivity reactions to medications. 30 Jul 2009
• Overcoming barriers to insulin replacement. 30 Jul 2009
• Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). 25 Jul 2009
• [How to calm diabetic patients? About the difficulty of counting to 4] 21 Jul 2009
• ["Educating patients about the study"] 21 Jul 2009
• [Depot insulin with tumor risk. Changing now or staying cool? (interview by Sarah Pampel)] 21 Jul 2009
• Insulin glargine and malignancy: an unwarranted alarm. 15 Jul 2009

See a longer list of these articles.

Technical information about 'Insulin'

Definition: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

Chemical name: Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-

Registry Number: 11061-68-0

Descriptor UI: D007328

Alternative terms: Insulin; Insulin, Regular; Regular Insulin; Humulin S; Iletin; Insulin A Chain; Insulin, Globin Zinc; Globin Zinc Insulin; Velosulin; Insulin, Regular, Human; Insulin, Regular, Pork; Novolin; Sodium Insulin; Insulin, Sodium; Type I Insulin; Insulin, Type I; Type II Insulin; Insulin, Type II; Humulin; Insulin, Regular, Beef-Pork;

Related Mesh Headings: Hyperinsulinism; Nonsuppressible Insulin-Like Activity; Proinsulin; Receptor, Insulin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Hypoglycemic Agents;

Tree Number: D06.472.699.587.740.625; D12.644.548.586.740.625;

Technical Notes: /blood: consider also HYPERINSULINEMIA (excessively high blood insulin levels) but do not confuse with HYPERINSULINISM (excessive secretion of insulin by pancreas); /immunology: consider also INSULIN ANTIBODIES; precursor = PROINSULIN; INSULIN INFUSION SYSTEMS is available